The current challenges for commercializing Israel’s cutting-edge Life Science technologies: Great infrastructure to push innovation into development but failure to move from development to market:
Israel has a good early-stage development infrastructure (via the incubator system) as well as good early-stage funding mechanisms throughout the development phase (via the Office of the Chief Scientist – OCS). However, as companies are preparing to ‘Go to Market’ they face two challenges: The ‘Managerial’ challenge – lack of commercial, regulatory, and operational experience needed for the transition from development and into the commercial phase; and the ‘Funding Abyss’ - the lack of appropriate funding mechanisms once companies leave the ‘early stage’ and require substantial growth capital to go to market.

Biomedix can provide the solution: Biomedix’s value is derived from its unique combination between Israel’s powerful incubator infrastructure and late-stage financing & management.
Through its control over two of Israel’s largest incubators (ATI, Meytav), Biomedix possesses a direct access into the entire array of Israel’s early-stage Life Science innovation, and via its late-stage Investment arm (SpearHead), Biomedix is able to help manage and fund its mature-winner companies by cherry-picking the best opportunities from Israel’s entire Life Science landscape.

Business Model transforms early-stage incubator opportunities into later-stage, actively-managed companies
	CSO Funding Low financial risk 10-12 new companies annually
	Cherry-pick from incubators or external Intimate knowledge of companies prior to investment Superb investment terms Biomedix active management